A Phase 1 Double Blind (3rd Party Open) Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Repeat Doses Of Pf-06372865 In Subjects Aged 18-55 (Group 1) And 56-75 Years (Group 2)
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2014
At a glance
- Drugs PF 6372865 (Primary)
- Indications Pain
- Focus Pharmacokinetics
- Sponsors Pfizer
- 15 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 Apr 2014 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.